Menu
POTENTIAL DEAL DETAILS
| Stock | Evolent Health Inc. | Symbol | EVH |
| Date Announced | 08/22/2024 | Source | Reuters |
| Type | News Report |
Reuters reported that Evolent Health (EVH) is in talks with private equity firms and healthcare services providers for a potential sale, in a process that kicked off after it received takeover interest.
Private equity firms TPG (TPG), CD&R, and KKR (KKR) are among the parties that have expressed interest in a deal for healthcare software provider Evolent, which has a market value of about $3.8 billion. TPG was one of the early investors in Evolent.
Health insurer Elevance Health (ELV) is also among the bidders and could team up with a private equity firm to acquire Evolent.
Evolent, which is working with a financial adviser on the sale process that kicked off a few months ago, has received initial bids. A deal could be reached in the next few weeks.
Evolent Health Inc. Investor Relations
TPG Inc. Investor Relations
Clayton, Dubilier & Rice, LLC Investor Relations
KKR & Co. Inc. Investor Relations
Elevance Health Inc. Investor Relations
Update(s):
August 26, 2024: Reuters reported that health insurer Elevance Health (ELV) also initially expressed an interest in bidding for Evolent (EVH), but the company dropped out of the process.
Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.